Duchenne Muscular Dystrophy Clinical Trials in Los Angeles, California

4 studies are recruiting for duchenne muscular dystrophy in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

   Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and < 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preli…

   Stage

   Phase 2

   Ages

   7 to 9

   Site

   University of California Los Angeles, Los Angeles, California

   Locations

   21 in total

   Run by

   Satellos Bioscience, Inc.

   See if you can join NCT07287189 on ClinicalTrials.gov

2. A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

   Cohort 8 (non-ambulatory participants) is currently enrolling new participants. Enrollment for Cohorts 1 through 7 has been completed. This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with Duchenne Muscular D…

   Stage

   Phase 1

   Ages

   2 and older

   Site

   University of California, Los Angeles, Los Angeles, California

   Locations

   12 in total

   Run by

   Sarepta Therapeutics, Inc.

   See if you can join NCT04626674 on ClinicalTrials.gov

3. Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

   The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of life, as assessed by standardized patient-reported outcome measures (QoL questionnaires) in male patients aged 2 years an…

   Stage

   Not phased

   Ages

   2 and older

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   33 in total

   Run by

   Catalyst Pharmaceuticals, Inc.

   See if you can join NCT06564974 on ClinicalTrials.gov

4. A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

   This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participants 4 to < 7 years o…

   Stage

   Phase 1

   Ages

   0 to 17

   Site

   University of California, Los Angeles Medical Center, Los Angeles, California

   Locations

   15 in total

   Run by

   Solid Biosciences Inc.

   See if you can join NCT06138639 on ClinicalTrials.gov